ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$2.47 USD
+0.18 (7.86%)
Updated Jul 11, 2024 03:52 PM ET
After-Market: $2.46 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.47 USD
+0.18 (7.86%)
Updated Jul 11, 2024 03:52 PM ET
After-Market: $2.46 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Zacks News
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
by Zacks Equity Research
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ASLN) Outperforming Other Medical Stocks This Year?
Will ASLAN Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.
Will ASLAN Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor ASLAN Pharmaceuticals.
ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
by Zacks Equity Research
Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for March 29th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 29th.
Top Ranked Momentum Stocks to Buy for March 28th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 28th.
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
by Zacks Equity Research
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.